Sector: Health Care
Director information for MIRUM PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Christopher Peetz | Chief Executive Officer | 47 | ["Co-founder of the company","Chief Executive Officer since March 2019","Former President from December 2018 to January 2024","Entrepreneur-in-Residence at Frazier since May 2017","Former CEO of Flashlight Therapeutics, Inc.","Former Chief Financial Officer at Tobira Therapeutics, Inc.","Experience in financial planning, corporate strategy, and commercial roles","MBA from Stanford Graduate School of Business","B.S.B.A. in Finance, International Business and French from Washington University in St. Louis"] | [] | 2026 |
| Laura Brege | Senior Advisor | 68 | ["Over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries.","Former President and Chief Executive Officer of Nodality, Inc.","Held senior-level positions at Onyx Pharmaceuticals, Inc.","General Partner at Red Rock Capital Management.","Senior Vice President and Chief Financial Officer at COR Therapeutics Inc.","Chief Financial Officer at Flextronics, Inc."] | [] | 2026 |
| Laurent Fischer, M.D. | Director | 62 | ["President and Chief Executive Officer of Adverum Biotechnologies, Inc.","Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc","Chief Executive Officer of Tobira Therapeutics, Inc.","Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc.","President and Chief Executive Officer of Ocera Therapeutics, Inc.","President and Chief Executive Officer of Auxeris Therapeutics, Inc.","President and Chief Operating Officer of RXCentric.com, Inc.","Chief Medical Officer and Vice President of Corporate Development of MedVantx Inc.","Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck","Medical Director for the Virology Group at Hoffman-LaRoche, Ltd.","Board member of CTI BioPharma Corp.","Board member of AtaiBeckley Inc.","Board member of Lycia Therapeutics, Inc.","Board member of Shinobi Therapeutics, Inc.","Board member of Senti Biosciences","Board member of Teal Bio","Medical Degree from the University of Geneva","Doctorate in Medicine from the Geneva Medical School, Switzerland"] | [] | 2026 |
| Lon Cardon, Ph.D., FMedSci | President and Chief Executive Officer | 60 | ["President and Chief Executive Officer at The Jackson Laboratory","Former Chief Scientific Officer at BioMarin Pharmaceutical Inc.","Former Senior Vice President of Genetics, Alternative Drug Discovery and Target Sciences at GlaxoSmithKline plc","Former professor at the University of Oxford","Former professor of biostatistics and human biology at the University of Washington","Member of the board of directors for public pharmaceutical company Reneo Pharmaceuticals, Inc.","Elected fellow of the UK’s Academy of Medical Sciences","Elected fellow of the American Association for the Advancement of Science"] | [] | 2026 |
| Michael Grey | Chair of the Board | 73 | ["Co-founder of the company","Former Executive Chairman","Extensive experience in the pharmaceutical and biotechnology industries","Held senior positions at various companies","Past President and CEO roles at multiple pharmaceutical firms"] | [] | 2026 |
| Patrick Heron | General Partner | 55 | ["General Partner with Frazier Life Sciences","Experience in company formations and initial investments in biotechnology companies","Previous director roles in public biopharmaceutical companies","B.A. in Political Science from the University of North Carolina at Chapel Hill","MBA from Harvard Business School","Extensive business background in venture capital and life sciences"] | [] | 2026 |
| Saira Ramasastry, MS, M.Phil. | Director | 50 | ["Managing Partner of Life Science Advisory, LLC","co-founded Sanacor, Inc.","Chief Operating Officer since April 2022","investment banker with Merrill Lynch & Company","financial analyst in mergers and acquisitions at Wasserstein Perella & Co.","experience overseeing cybersecurity risks","served on the board of directors for public companies"] | [] | 2026 |
| Timothy Walbert | Senior Advisor | 59 | ["Chairman, president and chief executive officer of Horizon Therapeutics","President, chief executive officer and director of IDM Pharma Inc.","Executive vice president, commercial operations at NeoPharm Inc.","Divisional vice president and general manager, immunology at Abbott","Director of CELEBREX North America at G.D. Searle & Company","Sales and marketing roles at G.D. Searle, Merck & Co. Inc. and Wyeth","Serves on the boards of multiple biotechnology companies","Member of various leadership councils and advisory boards"] | [] | 2026 |
| William Fairey | Director | 62 | ["interim Chief Executive Officer of Respira Therapeutics, Inc.","Executive Vice President and Chief Commercial Officer at MyoKardia, Inc.","Executive Vice President and Chief Operating Officer at ChemoCentryx, Inc.","President of Actelion Pharmaceuticals US, Inc.","Regional Vice President, Australia Asia Pacific, of Actelion Pharmaceuticals Ltd.","President of Actelion Pharmaceuticals Canada Inc.","Vice President of Sales and Management Markets of Actelion Pharmaceuticals US, Inc.","serves on the boards of directors of Ascendis Pharma, Inc., Rein Therapeutics, Inc., and KalVista Pharmaceuticals, Inc.","B.S. in biology from the University of Oregon","M.B.A. from Saint Mary’s College"] | [] | 2026 |
